Remdesivir "No effect" WHO announces provisional results October 16th, 20:22
Regarding remdesivir, an antiviral drug that has been specially approved in Japan as a therapeutic drug for the new coronavirus, WHO = World Health Organization has conducted an international clinical trial and found that "almost" in improving the mortality rate of inpatients It seems that no effect was observed or no effect was observed at all. "
The U.S. pharmaceutical company that developed this has issued a statement that WHO data has not yet been rigorously validated and is inconsistent with the efficacy previously shown in other clinical trials. ..
On the 15th, WHO announced the preliminary results of clinical trials such as remdesivir, which was conducted in 11,266 hospitalized patients infected with the new coronavirus at 405 hospitals in 30 countries.
Of these, for remdesivir, we compared the course of more than 2,700 patients in the treated group and the non-treated group, and asked whether the patient's mortality rate was improved or the length of hospital stay was shortened. , It seems that no effect was observed. "
US pharmaceutical company of development makes a statement
Regarding remdesivir, research groups such as the National Institutes of Health released the final report of an international clinical trial on the 8th of this month, expecting the effect of shortening the recovery time of patients with the new coronavirus and preventing its aggravation. I was announcing the result that I could do it.
Gilead Sciences, the American pharmaceutical company that developed remdesivir, released a statement yesterday, with WHO data not yet rigorously validated, inconsistent with efficacy previously shown in other clinical trials. They are showing concern, such as doing so.
WHO will continue to conduct clinical trials of other therapeutic agents in order to establish a treatment method.
Expert "Need to look calmly"
Regarding remdesivir, WHO announced the preliminary results of international clinical trials, said Professor Kazuhiro Tateda of Toho University, the chairman of the Japanese Society for Infectious Diseases, "The data presented this time is based on many cases. However, the results are noteworthy. However, the data currently published are before official papers, and scientifically, the results are until the research methods are properly verified and published as papers. It is necessary to look calmly at. It seems that a lot of verification including other studies is necessary to determine the evaluation of remdesivir. "